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Abstract
Aneurysmal subarachnoid hemorrhage (SAH) is a devastating neurological syndrome, 
which occurs at a rate of 3–25 per 100,000 population. Smoking and hypertension are the 
most important risk factors of subarachnoid hemorrhage. Rupture of cerebral aneurysm 
leads to rapid spread of blood into cerebrospinal fluid and subsequently leads to sud‐
den increase of intracranial pressure and severe headache. Subarachnoid hemorrhage 
is associated with neurological (such as re‐bleeding and vasospasm) and systemic (such 
as myocardial injury and hyponatremia) complications that are causes of high mortal‐
ity and morbidity. Although patients with poor‐grade subarachnoid hemorrhage are at 
higher risk of neurological and systemic complications, the early and aggressive man‐
agement of this group of patient has decreased overall mortality by 17% in last 40 years. 
Early aneurysm repair, close monitoring in dedicated neurological intensive care unit, 
prevention, and aggressive management of medical and neurological complications are 
the most important strategies to improve outcome.
Keywords: albumin, aneurysmal subarachnoid hemorrhage, vasospasm, re‐bleeding, 
hyponatremia, cardiac complication, coiling, clipping
1. Introduction
Subarachnoid hemorrhage (SAH) is a devastating disease and is associated with high mortal‐
ity and poor outcomes among survivors, management by multidisciplinary team is associated 
with improved outcomes; however, intensive care management presents big challenge. Most 
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of spontaneous SAH is due to the rupture of saccular aneurysm, the prevalence of intracranial 
saccular aneurysm by radiographic and autopsy series is 5%, about 20–30% of patients have 
several aneurysms [1].
Aneurysmal SAH (aSAH) occurs at a rate of 2–16 per 100,000 population, mostly occurring 
between 40 and 60 years of age; however, young children and elderly can be affected. The inci‐
dence of SAH is higher in women than men, which may be due to hormonal status. African 
Americans are at a higher risk of SAH than Caucasian Americans. Mortality rate is about 60% 
within first 6 months [2, 3].
2. Circle of Willis
The circle of Willis is an anastomotic structure. It is formed when the internal carotid artery 
enters the cranial cavity bilaterally and divides into the anterior cerebral artery and middle 
cerebral artery, and the anterior cerebral arteries are then united by an anterior communi‐
cating artery. These anastomoses form the anterior half of the circle (anterior circulation). 
Posteriorly, the basilar artery branches to give left and right posterior cerebral artery (poste‐
rior circulation). Posterior cerebral arteries join the internal carotid system anteriorly to com‐
plete the circle via posterior communicating arteries. Figure 1 shows the common sites of 
cerebral aneurysm [4, 5].
Figure 1. Common sites of cerebral aneurysm [5].
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3. Etiology
Subarachnoid hemorrhage is defined as bleeding into the space between the arachnoid and 
pia mater of the meninges enclosing the brain (subarachnoid space). The most common rea‐
son for spontaneous (non‐traumatic) SAH is the rupture of a cerebral aneurysm (85%) [5].
In about 15% of non‐traumatic SAH, no bleeding cause is identified by digital subtraction angi‐
ography (DSA). In these scenarios, differentiation between perimesencephalic and non‐perimes‐
encephalic location of the SAH is very important to determine further therapeutic approach [3].
Perimesencephalic SAH (PMSAH) is defined by the absence of an aneurysmatic bleeding and 
the classic presence of blood within the perimesencephalic and prepontine cisterns [3].
Computed topography angiogram (CTA) and magnetic resonance angiography (MRA) have 
high sensitivity of excluding aneurysmal bleedings in PMSAH.
PMSAH has less complication and better prognosis than aneurysmal SAH.
Non‐perimesencephalic is  SAH without bleeding source in the baseline DSA, the chance 
of positive findings in a follow‐up angiography fluctuated between 5 and 35%, that is why 
DSA should be repeated not before 3 weeks after the initial bleeding if there are no other 
therapeutic indications [3].
Non‐traumatic SAH can be caused by various other non‐aneurysmatic causes (Table 1), and 
the management of these cases must be performed according to the underlying cause [3].
Disease Example
Infectious arterial vasculitis Mycotic (infectious) aneurysm
Meningovascular lues
Lyme disease
Gnathostomiasis (Gnathostoma spinigerum)
Immune vasculitis Primary CNS angiitis
Polyarteritis nodosa
Wegener's vasculitis
Churg‐Strauss syndrome
Behçet's disease
Other cerebrovascular diseases Arteriovenous angioma
Dural arteriovenous fistula
Spinal arterial aneurysm
Intracranial arterial dissection
Venous sinus thrombosis
Cerebral amyloid angiopathy
Moyamoya disease
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4. Risk factors
Most spontaneous SAHs result from the rupture of intracranial aneurysms; therefore, risk 
factors for aneurysm formation overlap with risk factors for SAH.
(1) Cigarette smoking: It is associated with 11‐fold increased risk of SAH. Worldwide, it is 
the most important preventable risk factor, which has been proved in numerous cohort 
(relative risk, RR, of current smoking, 2.2) and case‐control studies (odds ratio, OR, 3.1); 
cigarette smoking also hastened aneurysm growth rate [2, 3].
(2) Hypertension: It is a major risk factor for SAH and possibly for aneurysm formation and 
fatal aneurysm rupture. Treatment of hypertension may reduce the risk of aneurysmal 
SAH [6].
(3) Alcohol abuse: Excessive alcohol abuse raises the possibility for SAH independent of 
cigarette smoking, age, and history of hypertension [3].
(4) Genetic risk: The risk of SAH increases seven folds in first‐degree relatives of patient; in 
addition, number of rare inherited conditions (Autosomal dominant polycystic kidney, 
Ehler‐Danlos syndrome) are associated with cerebral aneurysm and SAH [2, 6].
(5) Use of sympathomimetic drugs such as (cocaine) [6].
(6) Female sex: This is believed to be due to estrogen deficiency (estrogen replacement thera‐
py reduces the risk), so it is higher in postmenopausal women than premenopausal ones 
[3, 6].
(7) Antithrombotic therapy: It increases the severity of the hemorrhage, there are no data to 
prove whether antithrombotic therapy increases the risk of aneurysmal rupture or not 
[3, 6].
(8) Inflammation seems to play a vital role in the pathogenesis and growth of intracranial 
aneurysms. Prominent mediators include the nuclear factor k ‐ light‐chain enhancer of 
activated B cells (NF‐κB), tumor necrosis factor, macrophages, and reactive oxygen spe‐
cies. Although there are no controlled studies in humans, 3‐hydroxy‐3‐methylglutaryl 
coenzyme A reductase inhibitors (statins) and calcium channel blockers could impede 
aneurysm formation by the inhibition of NF‐κB and other pathways [6, 7].
Disease Example
Tumor Intracranial und intraspinal tumor
Hematology Sickle cell anemia
Drugs Anticoagulants and thrombolytic therapy
Substance abuse Cocaine
Table 1. Rare causes of non‐traumatic SAH [3].
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(9) Aneurysm size of 7 mm increases risk of rupture and subsequent SAH [6].
(10) Aneurysm morphology such as bottleneck shape and the ratio of size of aneurysm to par‐
ent vessels are associated with rupture of aneurysm [6].
(11) The risk of SAH increases in symptomatic patient with large unruptured cerebral aneu‐
rysm especially if it is located either on posterior communicating artery or on the verte‐
brobasilar system [6].
5. Pathophysiology
Smoking, chronic hypertension, and alcohol abuse lead to weakened arterial tunica media. 
Chronic exposure to intravascular shear stress leads to pouching of the weakened wall, espe‐
cially in the vicinity of bifurcations where turbulent flow is prominent.
The aneurysmal rupture is directly proportional to the size of the aneurysm, which is rising 
from 0.05% in aneurysms less than 10 mm to 6% for those greater than 25 mm.
More than 80% of cerebral aneurysm arises from the anterior carotid circulation (anterior and 
posterior communicating and middle cerebral arteries), with only 10–20% arising from the 
posterior vertebrobasilar circulation [1, 2].
Subsequent to aneurysmal rupture, blood spreads quickly within cerebrospinal fluid (CSF), 
rapidly increasing intracranial pressure (ICP), this sudden increase in the ICP leads to severe 
headache, cerebral edema, and hydrocephalus. Bleeding usually lasts for a few seconds; 
however, re‐bleeding is common and occurs within the first 24 h. The presence of blood and 
breakdown products of hemoglobin in the subarachnoid space is responsible for meningeal 
irritation, meningism, and vasospasm [2].
6. Clinical manifestation
Headache is the hallmark of aSAH in awake patient who describes it “as worst headache 
in their life,” this headache has a sudden onset and immediately reaches maximal inten‐
sity (thunderclap headache). Sentinel headache is also reported by 10–43% of patients, 
which is minor headache, and it is symptoms of minor hemorrhage (sentinel bleed or 
warning leak). Most of these minor hemorrhages occur within 2–8 weeks before major 
hemorrhage [6, 8].
The headache may be associated with nausea and/or vomiting, stiff neck, photophobia, brief 
loss of consciousness, or focal neurological deficits (including cranial nerve palsies).
Seizures occur in about 26% of patients within the first 24 h of SAH, most of the time 
before medical care is accessed. It is common in presence of intracerebral hemorrhage, in 
hypertensive patients, and patient with middle cerebral or anterior communicating artery 
aneurysms [6].
Aneurysmal Subarachnoid Hemorrhage
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7. Diagnosis
7.1. Non‐contrast head CT scan
Non‐contrast CT scan is the cornerstone of SAH diagnosis, it confirms the presence of 
blood clot in subarachnoid space in most of the cases if the scan is performed in the first 
24 h, and it may also provide an idea of the cause of the bleeding and site of the aneurysm. 
In addition to that, it is useful in diagnosis of intraventricular and subdural hematoma 
[2, 6].
CT scan sensitivity is highest in the first 3 days (close to 100%) and progressively decreases 
over time to about 58% in the fifth day [6].
7.2. Lumbar puncture
The typical findings are an elevated opening pressure and presence of xanthochromia, which 
can last for 2 weeks after SAH. Xanthochromia represents hemoglobin degradation products 
in CSF and indicates that the blood has been in CSF for at least 2 h [6, 9].
7.3. Brain MRI
MRI has advantages over CT brain in detection of subacute subarachnoid hemorrhage (after 
4 days), when head CT scan is negative and there is clinical suspicion of SAH, and possibly 
avoiding the need of lumbar puncture. The most important disadvantages are difficulty in 
scanning acutely confused ill patient, without sedation for at least 45 minutes, predisposing 
to motion artifact, and is expensive in comparison with CT [6].
7.4. Digital subtraction angiography (DSA)
Once diagnosis of SAH has been completed, the source of bleeding must be identified with 
angiographic studies. Digital subtraction angiography (DSA) is the gold standard for the 
detection of intracranial aneurysm and study of anatomical features of cerebral blood vessels 
[3, 6].
7.5. CT and MR angiography
Both CT and MR angiography are useful for screening and pre‐surgical planning, they can 
detect aneurysms ≥3 mm with high degree of sensitivity; however, they are less sensitive 
than conventional angiography. CTA can be achieved immediately after the diagnosis of 
SAH by CT scan when the patient is still in scanner; CTA is more practical than MRA in 
acute setting. CTA is used as an alternative to conventional angiography in SAH patients, 
especially in acute setting and rapidly declining patient who needs emergent craniotomy for 
hematoma evacuation. CTA can substitute catheter cerebral angiography in older patient with 
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 degenerative vascular disease provided that the quality is excellent and investigation is per‐
formed cautiously. Negative CTA should be followed by two‐ and three‐dimensional cerebral 
angiography in case of diffuse SAH [3, 6]. MRA is rarely indicated in SAH, because of limited 
routine availability, difficulty in scanning acutely sick patient, who is poorly compliant to 
commands, which can affect quality of the study, moreover MRA is time consuming and very 
expensive [6].
8. Grading of SAH
Hard work has been made for the development of scales to clinically grade patients with SAH, 
to assess the severity of initial injury, to guide treatment decision, to provide  prognostic 
 information regarding outcome, and to standardize patient evaluation for scientific study 
purposes. Since 1933, more than 40 grading systems have been proposed for patients with 
cerebral aneurysm. Currently, the most commonly used SAH grading scales are the Hunt and 
Hess scale, Fisher scale, Glasgow Coma Scale (GCS), and the World Federation of Neurological 
Surgeons (WFNS) scale [10].
8.1. World Federation of Neurosurgeons SAH Scale (WFNS)
In 1998, an expert judgment committee projected the WFNS scale, it was based on GCS and 
the presence of focal neurological deficit (Table 2). Numerous studies found direct association 
between WFNS grade and outcome [10].
8.2. Prognosis on Admission of Aneurysmal Subarachnoid Hemorrhage (PAASH)
PAASH is solely based on the GCS; it has excellent internal and external validity in regard to 
clinical outcome. In a study comparing prognostic accuracy of WFNS and PAASH, PAASH 
had a good prognostic value for patient outcome (Table 3) [3].
WFNS scale GCS Motor deficit, aphasia±hemiparesis or hemiplegia
I 15 Absent
II 14–13 Absent
III 14–13 Present
IV 12–7 Present/absent
V 6–3 Present/absent
Table 2. World Federation of Neurosurgeons SAH scale.
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8.3. The Hunt and Hess scale
The Hunt and Hess scale was projected in 1968 as an adjustment to an older system initially 
described by Botterell and colleagues in 1956. The scale was prepared to stratify the surgical 
risk and to help the surgeon on making appropriate decision in appropriate time. It is well 
known in the neuroscientific community; however, many of the terms used to define grades, 
such as drowsy, stupor or deep coma, headache (mild, moderate, severe), nuchal rigidity 
(slight vs. sever), are subjective and vague which makes this grading system neither reliable 
nor valid (Table 4) [3, 10].
8.4. Fisher scale
In 1980, the Fisher scale was projected to predict cerebral vasospasm after SAH (Figure 2), 
the scale quantifies the amount of blood seen on CT scan (Table 5). It was developed when 
 imaging technology had roughly one‐tenth of the resolution currently available. Subarachnoid 
Grade Clinical description
I Asymptomatic or minimal headache and slight nuchal rigidity.
II Moderate to severe headache, nuchal rigidity, no neurological deficit other than cranial nerve palsy.
III Drowsiness, confusion, or mild focal deficit.
IV Stupor, moderate to severe hemiparesis, and possibly decerebrate rigidity and vegetative disturbances.
V Deep coma, decerebrate rigidity, moribund appearance.
Table 4. Hunt and Hess scale.
Scale Grade Criteria Proportion of patient with poor outcome (%)
WFNS I GCS 15 14.8
II GCS 13–14 no focal deficits 29.4
III GCS 13–14 focal deficits 52.6
IV GCS 7–12 58.3
V GCS 3–6 92.7
PAASH I GCS 15 14.8
II GCS 11–14 41.3
III GCS 8–10 74.4
IV GCS 4–7 84.7
V GCS 3 93.9
Table 3. Two SAH grading scales with criteria per grade and relation with outcome [3].
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clot less than 1 mm in true thickness is uncommon, as is the finding of no blood on admission 
CT scan, therefore, grades 1 and 2 were actually be quite uncommon [3, 10].
9. Complications associated with SAH
Complications of subarachnoid hemorrhage can be divided into CNS and systemic compli 
cations.
Group Blood on CT scan
I No subarachnoid detected.
II Diffuse or thin vertical layer <1 mm thick.
III Localized subarachnoid clot and/or vertical layer >1 mm thick.
IV Intraventricular or intra‐parenchymal clot with diffuse or no SAH.
Table 5. Fisher grade scale.
Figure 2. Scale grading system used to quantify the amount of subarachnoid hemorrhage and intraventricular 
hemorrhage (IVH). The percentages in the circles refer to the risk of vasospasm. Grades III and IV in the scale are the 
ones with the higher risk to develop “symptomatic vasospasm.” Adopted with permission from Ref. [11].
Aneurysmal Subarachnoid Hemorrhage
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9.1. CNS complications
Re‐bleeding, vasospasm, hydrocephalus, and seizures are the most important CNS compli‐
cations of SAH. The high rates of mortality and morbidity after aneurysmal subarachnoid 
hemorrhage are mainly due to CNS complications.
9.1.1. Re‐bleeding
Re‐bleeding occurs at a rate of 4–13% in the first 24 h, maximal risk of re‐bleeding is in the first 
2–12 h, most of re‐bleeding (73%) occurs within the first 72 h of initial hemorrhage. Re‐bleed‐
ing is associated with very high mortality and morbidity, especially if it occurs in the first 12 
h after the hemorrhage, the mortality rate reaches to 70% [6, 12].
Many factors are considered as predictor for re‐bleeding:
Hunt‐Hess grade on admission.
Maximal aneurysmal diameter.
High initial blood pressure.
Sentinel headache preceding SAH.
Longer interval from ictus to admission.
Ventriculostomy before aneurysmal treatment [6, 13].
Re‐bleeding diagnosis is based on the deterioration of neurological status and appearance 
of new hemorrhage in CT scan. Early securing of the aneurysm is the treatment of choice to 
prevent re‐bleeding; however, the optimum time for early intervention is unclear whether 
intervention within 24 h (ultra‐early) is superior to intervention after 3 days [12].
The management of high blood pressure after SAH is still debatable due to the lack of evi‐
dence from randomized controlled trial. Data from observational studies propose that aggres‐
sive management of blood pressure reduces the risk of re‐bleeding, however, at the expense 
of an increase in secondary ischemia. It looks acceptable but without strong evidence to 
stop all antihypertensive medications that the patients were taking,  and treat hypertension 
only when it is extremely high. It is very difficult to give limits for extreme blood pressures, 
because extreme varies between patients and it is affected by many factors such as previous 
blood pressure, cardiac disease, patient age, and other factors [3].
European stroke organization guidelines for the management of intracranial aneurysm and 
subarachnoid hemorrhage recommended that the systolic blood pressure should be kept less 
than 180 mmHg in patients with unsecured aneurysm, till the aneurysm is secured with coil‐
ing or clipping. They also recommended keeping mean arterial pressure (MAP) above 90 
mmHg when blood pressure is lowered [3].
Nicardipine is short‐acting calcium channel blocker, used for smooth control of blood pres‐
sure [3, 6].
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For patient with an unavoidable delay in obliteration of aneurysm, and great risk of re‐bleed‐
ing, short‐term (72 h) therapy with tranexamic acid or aminocaproic acid is advisable (pro‐
vided there is no medical contraindication) to decrease the risk of early bleeding. The overall 
outcome did not noticeably improve in patients treated with tranexamic acid, in spite of a 
remarkable decrease in re‐bleeding [3, 6].
In an uncontrolled study of 18 patients who received an intraoperative dose of Recombinant 
factor VIIa, no re‐bleeding was reported; however, one case had deep venous thrombo‐
sis (DVT) and seven had thrombosis in upper extremity in association with peripherally 
inserted central lines. Currently, there is no evidence to support the use of recombinant 
factor VIIa [3].
9.1.2. Vasospasm
Vasospasm is luminal narrowing of large cerebral blood arteries after SAH, leading to cerebral 
ischemia. Vasospasm commonly occurs 3–5 days after initial hemorrhage, with peak vasocon‐
striction occurring between days 5 and 14; it usually resolves spontaneously after 21 days of 
SAH. It may manifest in many features such as reduced conscious level, focal neurological 
deficit, and simply nuchal rigidity; the exclusion of other causes, such as re‐bleeding, hydro‐
cephalus, sepsis, and metabolic derangement, is required to confirm the diagnosis [6, 14, 15].
Sometimes there is no correlation between severity of vasospasm and the symptoms of isch‐
emia. There are patients with severe large artery spasm who never become symptomatic 
and others with quite modest spasm who develop infarction. Possibly various factors play 
important role in the development of ischemia and infarction, such as distal microcirculatory 
failure, poor collateral anatomy, and genetic or physiological variations in cellular ischemic 
tolerance. Vasospasm is confirmed angiographically in 70% of SAH patient , however  it mani‐
fests as symptomatic spasm in 36% of all patients  with SAH [6, 14, 15].
Age more than 80 years, smoking, hypertension, SAH clot volume (a higher Fisher's grade), 
location of aneurysm (vertebral artery, right sylvian fissure, pericallosal middle cerebral artery 
[MCA]), left ventricular hypertrophy, and treatment modality are the main risk factors for the 
development of cerebral vasospasm [15].
Digital subtraction angiography (DSA) is the gold standard diagnostic investigation to diag‐
nose vasospasm (reduced arterial diameter). Computed tomography angiography (CTA) and 
MRI studies are alternative investigations to DSA [15].
Transcranial Doppler sonography (TCD) can be used at the bedside to aid the diagnosis of 
vasospasm. The TCD criteria for vasospasm include a  mean flow velocity (MFV) greater 
than 120 cm/s, change in MFV value of more than 50 cm/s over 24 h, and Lindegaard ratio 
more than 3 (Lindegaard is a ratio derived from concurrent measurements of MFV in MCA 
and distal ipsilateral extracranial ICA). Diffusion‐perfusion mismatch on MRI is an useful 
investigation for the identification of early stages of vasospasm. Increase in motor‐evoked 
potential threshold more than 50 mA from the baseline value is an accurate indicator of 
vasospasm.
Aneurysmal Subarachnoid Hemorrhage
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Inflammatory marker such as C‐reactive protein has been investigated for its ability to predict 
vasospasm. In 93 SAH patients, postoperative and not preoperative C‐reactive proteins were 
associated with vasospasm and poor outcome with a cut‐off value of 4 mg/dL [15].
9.1.2.1. Pathophysiology of cerebral vasospasm
It is complicated. Various cascades in affected blood vessels and neurons are in play, they can 
be grouped into two categories.
9.1.2.1.1. Elevated intracellular calcium
After SAH, calcium influxes into smooth muscle and neuron is rapidly increased through 
N‐methyl‐D‐aspartate receptor (NMDA) and voltage‐gated calcium channels, moreover gluta‐
mate is increased and activates NMDA receptors, leading to further calcium influx in smooth 
muscle, high intracellular calcium concentration enhances binding of calcium to calmodulin. 
Calmodulin activates myosin light chain kinase (MLCK) to phosphorylate myosin, which induces 
myosin‐actin interaction and smooth muscle contraction and blood vessels constriction [14].
In neuronal cells, increase in intracellular calcium leads to hyperactivation of enzymes, such 
as protease, endonuclease, phospholipase, which destabilizes cell body and membrane, lead‐
ing to cellular injury and death [14].
9.1.2.1.2. Vasoactive compound and vessel wall injury
In days 3–5 after SAH, oxy hemoglobin—a red blood cell breakdown product—inhibits nitric 
oxide (physiologic vasodilator) and stimulates leukocytes to produce endothelin‐1 (physi‐
ologic vasoconstrictor), resulting in potent vasoconstriction. Furthermore, breakdown of oxy‐
hemoglobin leads to release of reactive oxygen species and iron which leads to oxidative 
damage to blood vessel walls [14].
In addition, production of vasoactive compounds after SAH, such as serotonin, norepineph‐
rine, and angiotensin II, leads to potent vasoconstriction [14].
9.1.2.2. Treatment of cerebral vasospasm and cerebral ischemia
9.1.2.2.1. Nimodipine
It is L‐type calcium channel blocker—it is the only drug that has been approved for SAH in 
European countries and the USA. It improves long‐term neurological outcome if it is started on 
admission and administered for 21 days. The recommended oral dosage is 60 mg 4 hourly orally 
(maximum daily dose 360 mg). The role of nimodipine is based on general brain protective 
mechanism as there is no proof to suggest that it treats angiographically diagnosed vasospasm, 
and it also increases fibrinolytic activity and inhibits cortical spreading ischemia [2, 6, 12, 15].
Recently, biodegradable silica‐based nimodipine implant was effectively used in the man‐
agement of vasospasm. It is associated with higher nimodipine cerebrospinal fluid (CSF) to 
plasma ratio than traditional nimodipine [15].
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The continuous intravenous infusion of nimodipine is not recommended as it is not superior 
to oral nimodipine and is associated with high incidence of hypotension especially in hypo‐
volemic patient (an adequate systolic BP of 130–150 mmHg takes priority over nimodipine 
administration, and it should be stopped if a stable BP can't be maintained).
The recommended dose of Intravenous nimodipine is 1 mg/h in the first 6 h, then increased to 
1.5 mg/h in next 6 h, then increased to 2 mg/h (maximum dose) [2, 6, 15].
9.1.2.2.2. Fasudil
It is Rho‐kinase inhibitor, it decreases smooth muscle contraction and inhibits TNF‐induced 
IL‐6 release from C6 glioma cells, and it causes better angiographic reduction in vasospasm 
and better neurological outcome than nimodipine. Fasudil is approved for use in Japan and 
China but not in the USA or Europe [12, 15].
9.1.2.2.3. Triple‐H therapy (hemodynamic augmentation therapy)
It is a combination of induced hypertension, hypervolemia, and hemodilution (HHH) to 
improve blood flow through narrowed cerebral blood vessels due to vasospasm. Triple‐H 
has been for years used as a treatment of choice for the treatment of delayed cerebral isch‐
emia, although the literature supporting its effectiveness and safety is lacking, in fact triple‐
H therapy is associated with an increase in the risk of systemic complications such as heart 
failure, pulmonary edema, and infections; therefore, the use of prophylactic triple‐H therapy 
is not recommended [3, 12].
Angiographic vasospasm without a new neurological deficit should not be treated. The 
development of unexplained  new neurological deficit or change in conscious level, imme‐
diate aggressive therapy should be started. The first step is a fluid bolus with normal saline 
to increase cerebral blood flow (CBF) in ischemic area, the goal is to maintain euvolemia. 
Hypervolemia and hemodilution do not increase cerebral oxygen delivery and might 
cause adverse events. If patients fail to respond completely to the fluid, management may 
undergo a trial of hypertension. Blood pressure is increased gradually with the use of a 
vasopressor. Neurological assessment should be repeated frequently in each blood pres‐
sure step (systolic blood pressure 180 mmHg / 190 mmHg / 200 mmHg), and the target 
should be based on neurological improvement. If the patient did not respond to induced 
hypertension (systolic blood pressure of 200–220 mmHg), a rescue cerebral angioplasty 
should be considered [12].
9.1.2.2.4. Balloon angioplasty
Cerebral angioplasty is indicated in symptomatic patient with cerebral vasospasm, who is not 
responding to hypertensive therapy, Prophylactic angioplasty is not recommended [2, 6, 12].
Cerebral angioplasty may lead to arterial dissection, rupture, thrombosis, infarction, hemor‐
rhage, and reperfusion injury leading to cerebral edema [6, 15].
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9.1.2.2.5. Intra‐arterial papaverine
Up to 300 mg of papaverine per hemisphere is used for the treatment of distal vasospasm.
The main disadvantages of intra‐arterial papaverine may require repeating, relatively short‐
acting, neurotoxic, seizures, blindness, coma, irreversible brain injury, arrhythmia, and hemo‐
dynamic instability refractory to treatment [2].
9.1.2.2.6. Magnesium sulphate
Currently, there is no evidence to support the use of magnesium sulphate (MgSO
4
) prophy‐
lactically or as a treatment modality in delayed cerebral ischemia (DCI). In the Mash 2 Trial, 
MgSO
4
 did not improve primary outcome. However, intrathecal and cisternal administration 
of MgSO
4
 significantly decreased the severity of vasospasm without any reduction in inci‐
dence of DCI or functional outcome [3, 6, 15].
9.1.2.2.7. Statins
Recent meta‐analysis reported no role of statin in SAH, and a larger phase 3 trial (Simvastatin 
in Aneurysmal Subarachnoid Hemorrhage [STASH]) failed to confirm any beneficial effect 
of statin for long‐ or short‐term outcome and should not be used routinely in acute stage 
[6, 12, 15].
9.1.2.2.8. Endothelin A‐receptor antagonist
Clazosentan (endothelin‐1 receptor antagonist) had been presented to be associated with a 
dose‐dependent decrease in the frequency of vasospasm in a phase IIb trial (Clazosentan to 
Overcome Neurological iSChemia and Infarct OccUrring after Subarachnoid hemorrhage 
[CONSCIOUS‐1]) [6, 15].
Two further trials were carried out:
CONSCIOUS‐2: A double blind, placebo‐controlled trial, clazosentan was given at a rate of 5 
mg/h for 15 days to patients treated with aneurysm clipping. There was statistically insignifi‐
cant decrease in mortality and vasospasm‐related morbidity [15].
CONSCIOUS‐3: This study was double blind, placebo‐ controlled study to assess whether 
clazosentan reduced vasospasm‐related mortality after securing aneurysmal SAH by endo‐
vascular coiling. The study was halted prematurely after completion of conscious‐2 trial and 
failed to show any beneficial effect of clazosentan.
It is worth noting that patient who received clazosentan had more pulmonary complications, 
anemia, and hypotension than the placebo group [6, 15].
9.1.2.3. Other miscellaneous treatments
9.1.2.3.1. Milrinone
In a large case series based on the assessment of all subarachnoid hemorrhage patients diag‐
nosed with delayed ischemic neurological deficit between April 1999 and April 2006, 88 
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patients were found to have received milrinone infusion for a median of 9.8 days. At 44.6 
months, 75% of them had a good functional outcome. Because of obvious limitations in this 
study, further studies are warranted [15].
9.1.2.3.2. Stellate ganglion block
A small study included 15 patients who had refractory cerebral vasospasm after surgical clip‐
ping of aneurysm. Stellate ganglion block was performed using 10 mL of bupivacaine 0.5% on 
the side with maximum cerebral blood flow velocity. Neurological status, cerebral blood flow 
velocity, and pulsatility index were assessed before and 10 min, 30 min, 2 h, 6 h, 12 h, and 24 h 
after stellate ganglion block. The ipsilateral Middle Cerebral Artery (MCA) mean velocity was 
reduced with reduction in neurological deficit and improvement in GCS; because of obvious 
limitations in this study, further studies are required [15].
9.1.2.3.3. Albumin
Albumin 25% has been tried to improve outcomes in a pilot study (Albumin in Subarachnoid 
Hemorrhage trial). The incidence of vasospasm, DCI, and cerebral infarction was significantly 
reduced with high dose of albumin; however, this is still experimental and further studies are 
required to support this study [12, 15].
9.1.3. Hydrocephalus
Hydrocephalus is one of the common complications of SAH; it is either acute or chronic.
Acute hydrocephalus occurs in 15–87% of  SAH patients  as a result of obstruction of CSF flow 
by blood products or adhesion, some clinician avoid insertion of a ventricular drain in these 
cases immediately as half of them will recover spontaneously and there is a risk of re‐bleed‐
ing and infection (meningitis and ventriculitis). Another approach recommended is to start 
immediate external ventricular drainage (keeping intracranial pressure between 10 and 20 
mm Hg), especially when obstructive hydrocephalus is suspected or when the lumbar drain‐
age is contraindicated (sever high intracranial pressure) [3, 6].
It has been recommended to apply lumbar drainage as a consecutive treatment of external ven‐
tricular drain (EVD) before shunting in cases with spontaneous intracerebral hemorrhage (ICH) 
when there is no blood in the third and fourth ventricles (communicating hydrocephalus). This 
option can be considered as an alternate approach to decrease the occurrence of permanent 
shunts, improve brain relaxation, and decrease risk of vasospasm; however, this approach may 
cause downward herniation in some cases such as supratentorial swelling and the development 
of hygroma. Currently no prospective clinical trial supports  lumbar drain insertion either for 
spontaneous ICH or cases with SAH [3, 6].
Acute hydrocephalus increases risk of  cerebral infarction and re‐bleeding and eventually 
may worsen the mortality and morbidity secondary to cerebral infarction and re‐bleeding 
[3, 6].
Chronic shunt‐dependent hydrocephalus, which occurs in 8.9–48% of patients with SAH due 
to a decrease in CSF absorption at the arachnoid granulation, it is usually treated with shunt 
placement [3, 6].
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Many factors are considered as predictor of hydrocephalus:
• Elderly.
• Intraventricular hemorrhage.
• Hypertension.
• Hyponatremia at presentation.
• Low Glasgow Coma Score at presentation.
• Antifibrinolytic agents.
9.1.4. Seizures
More than 26% of patients with SAH experience seizure‐like episodes, the majority of such 
patients report the onset of these seizures occurring before medical care are accessed. There 
are variable risk factors for the development of early seizures, such as aneurysm in middle 
cerebral artery, thickness of SAH clot, hypertension, intracerebral hematoma, re‐bleeding, 
cerebral infarction, and poor neurological grade. Routine use of anticonvulsants is associated 
with worsening of the cognitive function, delayed ischemia, fever, and vasospasm; however, 
it may be considered in patients with high risk of delayed seizure [3, 6].
9.2. Systemic complications associated with SAH
The high morbidity and mortality associated with SAH is not only due to neurological com‐
plications, non‐neurological complications also play a major role in increasing mortality and 
morbidity rates [16].
9.2.1. Cardiac complications
Cardiac complications occur in about 50% of patients with SAH; it ranges from mild elevation 
in cardiac enzymes and electrocardiogram (ECG) changes to obvious clinical and echocardio‐
graphic pathology. Cardiac damage markers are associated with an increased mortality and 
poor outcome and DCI [16].
9.2.1.1. Pathophysiology
9.2.1.1.1. Mild myocardial injury
This is presented by mild elevation in serum cardiac troponin I (not reaching diagnostic 
threshold of MI). This elevation occurs in 20–68% of patients with SAH. The degree of neuro‐
logical injury, as graded by the Hunt‐Hess scale, is an independent predictor of myocardial 
injury in SAH patients. Serum troponin is a powerful predictor for cardiac and pulmonary 
complications, such as hypotension requiring vasopressor, left ventricular (LV) dysfunction, 
pulmonary edema, and DCI, especially in patient presenting with a high grade on WFNS.
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Serum troponin is a more specific and sensitive indicator of myocardial injury than creatinine 
kinase‐MB; therefore, serum troponin levels and trends must be monitored through serial 
measurements particularly in SAH patients with past history of cardiovascular disease [16].
9.2.1.1.2. Cardiomyopathy
Neurogenic stunned myocardium (NSM) is the most severe form of myocardial injury in 
SAH, it occurs in 20–30% of patients with SAH. The elevated level of sympathetic tone leads 
to calcium overload with reduced sensitization of contractile filaments to this cation, eventu‐
ally causing myocardial depression. It is characterized by subendocardial contraction band 
necrosis.
Echocardiography shows abnormal LV contractility and abnormal wall motion, which are 
reversible but sometimes leads to cardiogenic shock [16].
CK‐MB levels, female gender, and poor neurological grade are predictors of LV dysfunction.
Severe LV dysfunction decreases cardiac output (CO) and mean arterial pressure leading to 
reduction in cerebral blood flow (CBF). Furthermore, LV dysfunction may be associated with 
cerebral vasospasm and significant decrease in cerebral perfusion pressure therefore, optimi‐
zation of heart function is critical to prevent progression of neurological dysfunction and to 
promote recovery in patients with SAH [2, 6, 16–18].
The use of inotropes such as dobutamine or milrinone may be required to optimize cardiac 
output (CO). In severe LV dysfunction, implementation of intra‐aortic balloon pump may be 
required [2, 6, 16, 18].
9.2.1.1.3. ECG findings
It is common in SAH patients, particularly in the first 3 days of presentation, nearly 50–100% 
of SAH patients will show different forms of ECG changes such as ST segments changes, T 
wave changes, QTc prolongation, and Prominent U wave (Table 6) [16, 17].
Around 4–8% of SAH patients will have malignant arrhythmias such as ventricular tachycar‐
dia (VT), torsade de pointe, and asystole [16, 18].
ECG abnormality Reported incidence (%)
ST‐segment changes 15–51
Inverted or isoelectric T waves 12–92
QTc prolongation 11–66
Prominent U waves 4–47
Sinus bradycardia 16
Sinus tachycardia 8.5
Table 6. ECG changes after subarachnoid hemorrhage [17].
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Management of arrhythmias in SAH patients depends upon the type of arrhythmia, clinical 
significance, and the patient's condition. As a first step, it is vital to assure satisfactory oxygen‐
ation and correct electrolyte abnormalities and metabolic disturbance.
The use of beta‐blockers to treat cardiac tachyarrhythmia in SAH should be balanced against 
hypotension and decrease in cerebral blood flow (CBF). A new study concluded that  the 
presence of  arrhythmias is  associated with poor outcome; in spite of this, no correlation 
was found between severity of cardiac arrhythmia and the site or the  extent of intracranial 
hemorrhage on CT scan, neurological condition, or the location of ruptured malformation [6, 
16, 18].
9.2.2. Electrolyte disturbance
The SAH is associated with different forms of electrolyte disturbances, such as hyponatremia, 
hypokalemia, hypocalcaemia, and hypomagnesaemia [6].
9.2.2.1. Hyponatremia
Hyponatremia is the most common clinically significant electrolyte derangement associated 
with SAH. It has an incidence ranging from 35 to 56 %, its diagnostic and therapeutic dilemma 
needs to be sorted to improve outcome of SAH patient [2, 16, 19].
Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the most common 
cause of hyponatremia; other causes are acute cortisol insufficiency, cerebral salt wasting syn‐
drome (CSW), extreme fluid therapy, and/or diuretic therapy.
Kao et al. stated that 34.5% of severe hyponatremia were secondary to SIADH, whereas 23% 
were considered to be due to CSW. Noteworthy, the patients recruited in this study had more 
severe SAH than in the comparative studies, and the inclusion criterion was a plasma Na <130 
mEq/L [19].
Irrespective of the cause, hyponatremia in SAH patients increases hospital stay, risk of vaso‐
spasm, and mortality rate.
The incidence of hyponatremia is associated with the location of aneurysmal rupture. 
Hyponatremia mostly occurs after rupture of anterior communicating artery (AComA). It 
was seen in 52.4% of patients with AComA; it may be because the hypothalamus is supplied 
by branch from AComA [19].
9.2.2.2. Causes of hyponatremia
SIADH is considered the most common cause of severe hyponatremia in SAH; it is secondary 
to excessive secretion of antidiuretic hormone as a result of stimulation of hypothalamus with 
traumatic or ischemic factor, causing increased water reabsorption in the distal convoluted 
tubule of the kidney, resulting in dilutional hyponatremia and fluid retention [19].
In CSW, the increase in urinary sodium  excretion  and urine output are due to abnormal release 
of atrial and brain natriuretic hormones, causing reduction in circulating blood volume, as well 
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as extracellular fluid. Cerebral salt wasting syndrome can be treated with hypertonic saline solu‐
tion which increases cerebral blood flow, brain tissue oxygen [19].
Clinically, it is very difficult to differentiate between SIADH and CSW syndrome, due to signifi‐
cant overlapping clinical findings between both syndromes: both syndromes are associated with 
brain lesions; have normal thyroid, adrenal, and kidney functions are hyponatremic, hypouri‐
cemic and have concentrated urines, high urinary sodium over 40 mEq/L, and high fractional 
excretion (FE) of urate. The only clinical difference is the state of their extracellular volume 
(ECV): being hypervolemic or euvolemic in SIADH and hypovolemic in CSW (Table 7) [20].
ECV assessment by usual clinical criteria is very difficult, not accurate to any degree [20].
Determination fractional excretion (FE) of urate is very helpful to differentiate between these 
syndromes, FEurate, normal 4–11%, has been constantly increased to >11% in both syndromes 
and has a distinctive relationship to serum sodium in both syndromes. In SIADH, correction 
of hyponatremia will normalize FEurate to 4–11% but in CSW syndrome FEurate consistently 
> 11% event after correction of hyponatremia (Figure 3).
This algorithm is useful only with normal glomerular filtration rate GFR, because FEurate can 
exceed normal values in patients with reduced glomerular filtration rate (GFR) [20].
Cortisol deficiency is one of the important causes of hyponatremia, which has not been well 
investigated in SAH patients because routine examination of adrenocorticotropic hormone 
(ACTH)/cortisol dynamic is not part of SAH work up [19].
Klose et al. and Parenti et al. investigated pituitary function post‐SAH and found that between 
7.1 and 12% of patients are cortisol‐deficient at the time of presentation with SAH [20].
SIADH CSW
Plasma volume ↑ or ↔ ↓↓
Water balance ↑ or ↔ Negative
Signs and symptoms of dehydration Absent Present
Central venous pressure ↑ or ↔ ↓↓
Salt balance Variable Negative
Hematocrit ↔ ↑ or ↔
Serum osmolality ↓↓ ↓↓
Urine sodium ↑ ↑↑
Urine volume ↓or ↔ ↑↑
Plasma BUN/creatinine ↓↓ ↑ or ↔
Treatment Fluid restriction, hypertonic saline, 
furosemide, demeclocycline
Normal saline, hypertonic 
saline, fludrocortisone
Table 7. Difference between SIADH and CSW [21].
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9.2.2.3. Treatment of hyponatremia
Patients with SAH should be closely monitored in an intensive care unit, preferably neurointen‐
sive care for at least 2–3 weeks post‐SAH, to allow for close monitoring of signs and symptoms 
of delayed cerebral ischemia (DCI), cerebral vasospasm, as well as fluid and electrolyte balance 
on daily basis, which can help treating doctors in early detection and efficient management 
of hyponatremia. A daily follow‐up of electrolyte is ideal and should be routine. If patients 
require intravenous hypertonic saline, sodium level should be checked every 4 h.
Urgent investigations of sodium level are mandatory if there are changes in mental status, 
massive fluctuation of fluid balance, and/or polyuria.
Rapid correction of hyponatremia can cause central myelinolysis and should be avoided, 
but insufficient correction of hyponatremia can result in brain edema, convulsion, and death 
[17, 20–22].
Fluid restriction to correct hyponatremia is associated with increased risk of cerebral vaso‐
spasm [19, 23].
Audibert et al. looked at the endocrinological response to severe SAH and found altera‐
tions in plasma level of numerous hormones such as aldosterone, renin, ADH, angiotensin, 
ANP, and BNP. However, these changes are noted during the first 12 days post‐SAH. It is 
Figure 3. Algorithm for determining the cause of hyponatremia, using FEurate.
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not practical to correctly and promptly get hormone levels, because their profile fluctuates 
frequently.
The expertise recommended that assessing bedside sodium and fluid balance is the best valu‐
able and economical technique for avoiding hyponatremia in patients with SAH [17].
Traditionally, patients with SAH are maintained on sodium chloride‐based fluids (i.e., 0.9% 
saline) for baseline and fluid replacement requirements, to avoid cerebral edema due to fluid 
shifts across a damaged blood‐brain barrier [19].
The recent guidelines of the Neurocritical Care Society for the management of patients with 
SAH suggested avoiding large amounts of free water intake and fluid restriction to treat 
hyponatremia [19].
In addition, the guidelines of the American Heart Association recommend that volume contrac‐
tion be replaced with isotonic fluids (Class IIa, Level B evidence) and that large volumes of hypo‐
tonic fluids should be avoided in patients with SAH. The guidelines, however, did not make 
recommendations on the composition of baseline fluid administration in SAH patients [17].
Recently, Lehmann et al. suggested balanced crystalloids and colloid solutions (those with 
electrolyte compositions similar to plasma) in SAH patients, which do not cause frequent 
hyponatremia or hypo‐osmolality, also prevent electrolyte imbalance such as hyperchlore‐
mia, hyper osmolality, and extreme positive fluid balances associated with saline‐based intra‐
venous fluids [19, 24].
Fluid restriction to less than 500 mL/day is the treatment of choice in SIADH, although such 
approach may not be feasible in SAH, because fluid restriction can cause cerebral vasospasm 
and subsequently cerebral infarction. What's more, most of these patients are not fully con‐
scious and require enteral feeding which results in a daily fluid intake of 1–2 L [19, 25].
Therapeutic options for water restriction include hypertonic saline solutions and albumin 
[19]. Hypertonic saline (2–3% solution) not only increases plasma sodium concentration effi‐
ciently and rapidly but also increases the risk of pulmonary edema and heart failure and 
neurological complications secondary to the increase in blood volume [19].
Fludrocortisone causes sodium retention, but it is associated with fluid overload and limited 
evidence of its effectiveness [19].
Vasopressin receptor antagonists such as conivaptan have been projected and trialed in small 
studies but have not become routine therapy, because harmful effect secondary to the rapid 
increase in plasma sodium (4–6 mEq/L) [19, 26].
Acute cortisol deficiency is typically corrected with administration of parenteral hydrocortisone, 
but the  beneficial effect of hydrocortisone is still uncertain and further studies are required, 
because it is not clear whether corticosteroid therapy is effective in management of acute relative 
adrenal insufficiency after SAH  [19, 27].
Overall, the management of hyponatremia in SAH patients necessitates additional investiga‐
tion of treatment options that avoid fluid restriction, and further studies will help standardize 
ideal care.
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9.2.3. Fever
Fever is one of the common medical complications of SAH and occurs in 70% of SAH patients. 
Fever may be due hypothalamic effect of the hemorrhage; it is associated with the severity 
of the injury, amount of hemorrhage, and development of vasospasm. Effective fever man‐
agement may improve functional outcome. Paracetamol is the treatment of choice for fever. 
Active cooling is very effective but adverse effects of shivering may offset its benefit [6, 17].
It is worth noting that the infectious cause such as pneumonia needs to be excluded [17].
9.2.4. Anemia
Anemia is very common and is associated with poor outcome, due to compromising brain 
oxygen delivery. Correction of anemia and high hemoglobin value improve outcome after 
SAH. Current guidance recommends to keep hemoglobin concentration between 8 and 
10 g/dL [17].
9.2.5. Thrombocytopenia and deep venous thrombosis (DVT)
Heparin‐induced thrombocytopenia (HIT) is directly associated with the number of angio‐
graphic procedures have been performed. Patients with heparin‐induced thrombocytopenia 
type II seems to be at high risk of thrombotic complications, vasospasm, and poor outcome.
Currently, it is uncertain whether there is practical means of avoiding HIT (as it is essential 
in angiographic procedures); however, it is vital to know this complication to avoid further 
heparin exposure and to use non‐heparin substitute under the supervision of a hematologist.
DVT is relatively recurrent event after SAH, especially in immobilized patients [3, 6].
Table 8 and Figure 4 summarize the incidence rate of non‐neurological complications.
Complications Incidence (%)
Fever 54
Anemia 36
Hyperglycemia 30
Hypertension 27
Hypernatremia 22
Pneumonia 20
Hypotension 18
Pulmonary edema 14
Hyponatremia 14
Life‐threatening arrhythmia 8
Myocardial ischemia 6
Table 8. Non‐neurological complications of subarachnoid hemorrhage [17].
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10. Surgical and endovascular methods for treatment of ruptured cerebral 
aneurysms
Ruptured aneurysms can be cured by microsurgical clipping or endovascular coiling.
Microsurgical clipping requires craniotomy to prevent re‐bleeding of the aneurysm via inser‐
tion of a clip through its neck, thus isolating the aneurysm from circulation. This technique 
conveys a 98% certainty of elimination of the risk of rupture [29].
Endovascular coiling is the  blocking of an aneurysm by an endovascular approach with electri‐
cally detachable platinum coils device which induces secondary thrombosis of the aneurysm [6]. 
The first published prospective randomized outcome study of surgical versus endovascular coiling, 
concluded that endovascular treatment results in clinical outcomes equal to that of surgical clipping.
Koivisto and co‐worker (2000) published first prospective randomized outcome study of 
surgical versus endovascular coiling, they concluded that endovascular treatment results in 
clinical outcomes equal to that of surgical clipping [30].
The International Subarachnoid Aneurysm Trial (ISAT) is the first multicenter prospective 
randomized trial comparing the two options; the included 2143 patients with ruptured intra‐
cranial aneurysms were randomly assigned to clipping (1070) or coiling (1073). Primary out‐
comes included death or dependent living, and secondary outcomes included risk of seizures 
Figure 4. Harmful effects of SAH on extracerebral organs [28].
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and risk of re‐bleeding. Initially, 1‐year outcomes concluded a fall in death and disability from 
31% in the clipping arm to 24% in the endovascular arm, this difference was mainly driven by 
a reduction in the rate of disability among survivors (16% in the endovascular arm and 22% 
in the clipping arm) [6, 29, 30].
The risk of epilepsy and significant cognitive decline was also reduced in the endovascular 
group, but the occurrence of late re‐bleeding was increased in endovascular group (2.9% after 
endovascular repair vs. 0.9% after open surgery) and only 58% of coiled aneurysms were 
completely obliterated compared with 81% of clipped aneurysms [6].
Although these results have affected the approach to patients with intracranial aneurysm in 
neurosurgical centers across the world, the study has been criticized due to the lack of gen‐
eralizability, for example, posterior circulation aneurysms, which account for 8% of patients 
admitted with subarachnoid hemorrhage and up to 48% of ruptured aneurysms managed by 
endovascular coiling at some centers, made up only 2.7% of the ISAT study population [30].
Tahir et al. [29] concluded no significant difference in the clinical outcome of coiling and clip‐
ping of ruptured intracranial aneurysms; however, clipping is more cost effective than coiling.
Clipping is recommended for middle cerebral artery aneurysms (difficult to treat with endo‐
vascular technique) and patients presenting with an intraparenchymal hematoma >50 mL (high 
occurrence of critical outcome). Endovascular coiling is the preferred technique for patients 
presenting with vasospasm, elderly, poor clinical grade, and posterior cerebral aneurysms [6].
11. Time of surgical intervention
The most important strategy to reduce the risk of aneurysm rupture is early aneurysm repair, 
although evidence for best time of intervention is limited, it is uncertain whether ultra‐ early 
treatment (before 24 h) is better than aneurysm repair within 72 h (early). Recently published 
data analysis suggested that the surgical intervention can be done safely within 72 h after 
SAH. The American Heart Association/American Stroke Association recommend that “surgi‐
cal clipping or endovascular coiling of the ruptured aneurysm should be performed as early 
as feasible in the majority of patients to reduce the rate of re‐bleeding after SAH” (Class 1B). 
This recommendation is supported by the European Stroke Organization Guidelines for the 
Management of Intracranial Aneurysms and Subarachnoid Haemorrhage, which indicated 
that “aneurysm should be treated as early as logistically and technically possible to reduce 
the risk of re‐bleeding; if possible it should be aimed to intervene at least within 72 hours after 
onset of first symptoms.” There is ongoing study that only recruiting SAH with poor grade 
may help answer the question of whether intervention within 72 h (early intervention) is asso‐
ciated with better outcome compared with intervention within 4–7 days [12].
12. Prognosis and outcome
In spite of improvement in interventional and medical treatment of SAH, rupture of an aneu‐
rysm is still associated with significant high mortality rates (about 33%) and sever disability 
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(17%). In last decades, mortality rates decreased by 17%, and the chance to recover to inde‐
pendent state has increased by 1.5% per year. Severity of initial bleeding plays a vital role in 
the determination of mortality rate and functional outcome [3].
Age is another important factor: mortality rate increased three times if the patient was older 
than 80 years. Aneurysm size, site, history of hypertension, high systolic pressure, history of 
alcohol consumption, cigarette smoking are all important factors associated with poor out‐
come regardless the severity of SAH [3].
Complications such as re‐bleeding, DCI, hydrocephalus, hyperglycemia, metabolic distur‐
bances, cardiopulmonary complications, prolonged bed rest are associated with increased 
probability of poor outcome.
Small studies suggest that increased catecholamine levels in cerebrospinal fluid (CSF) are 
associated with early mortality or disability. Serum S100 is another marker of poor outcome 
after SAH [3].
13. Conclusion
Aneurysmal SAH is a devastating neurovascular disease associated with very high mortality 
and morbidity despite improvement in interventional and medical treatment due to mul‐
tiple neurological and systemic complications, especially re‐bleeding and DCI secondary to 
vasospasm. Age, smoking, alcohol consumption, hypertension, site and size of aneurysm are 
important factors associated with poor outcome. SAH needs multidisciplinary specialized 
care, best provided in high‐volume centers to improve outcome.
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